RxDoctor Payments Data

Joanne Crenshaw, MD

Ophthalmology · Sterling, VANPI 1225120538

Payments from drug & device makers

$2,444in general payments, 2019–2025

Across 80 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$944
  • Sun Pharmaceutical Industries Inc.$273
  • Mallinckrodt Hospital Products Inc.$206
  • Bausch & Lomb Americas Inc.$197
  • Alcon$195
  • Glaukos Corporation$144
  • plus $485 from 11 others

What the payments were for

  • Food & beverage$2,444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,444 in reported general payments places this provider in the 70th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$121,356
Medicare patients
472
Services billed
1,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost51$33,410
RestasisCyclosporine26$31,082
VyzultaLatanoprostene Bunod67$25,320
Alphagan PBrimonidine Tartrate45$13,229
AzoptBrinzolamide15$8,323
Cyclosporine19$6,992
SimbrinzaBrinzolamide/Brimonidine Tart12$5,097
Dorzolamide-TimololDorzolamide/Timolol/Pf28$4,757
Travoprost15$3,350
Timolol Maleate39$3,149
Brimonidine Tartrate39$2,119
Latanoprost138$1,093
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat33$641
Dorzolamide Hcl30$598
Prednisolone Acetate14$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$944$77,720122 claims
Bausch & Lomb Americas Inc.Vyzulta$197$25,32067 claims
AlconAzopt, Simbrinza$195$13,42027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Sterling

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →